Implementation of a psychosocial support package for people receiving treatment for multidrug-resistant tuberculosis in Nepal: A feasibility and acceptability study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
      Counseling* ; Social Support*; Tuberculosis, Multidrug-Resistant/*psychology ; Tuberculosis, Multidrug-Resistant/*therapy; Adult ; Feasibility Studies ; Female ; Humans ; Male ; Nepal ; Patient Acceptance of Health Care ; Patient Education as Topic ; Patient-Centered Care ; Pilot Projects ; Qualitative Research ; Young Adult
    • Abstract:
      Background and Objectives: People receiving treatment for multidrug-resistant tuberculosis (MDR-TB) have high rates of depression. Psychosocial support in general, and treatments for depression in particular, form an important but neglected area of patient-centred care, and a key pillar in the global End TB strategy. We assessed the feasibility and acceptability of a psychosocial support package for people receiving treatment for MDR-TB in Nepal.
      Methods: This feasibility study used a mixed quantitative and qualitative approach. We implemented the intervention package in two National Tuberculosis Programme (NTP) MDR-TB treatment centres and 8 sub-centres. We screened patients monthly for depression and anxiety (cut-off ≥24 and ≥17 respectively on the Hopkins Symptom Checklist) and also for low social support (cut-off ≤3 on the Multidimensional Scale of Perceived Social Support). Those who screened positive on either screening tool received the Healthy Activity Program (HAP), which uses brief counselling based on behavioural activation theory. Other aspects of the psychosocial package were information/education materials and group interactions with other patients.
      Results: We screened 135 patients, of whom 12 (9%) received HAP counselling, 115 (85%) received information materials, 80 (59%) received an education session and 49 (36%) received at least one group session. Eight group sessions were conducted in total. All aspects of the intervention package were acceptable to patients, including the screening, information, group work and counselling. Patients particularly valued having someone to talk to about their concerns and worries. We were able to successfully train individuals with no experience of psychological counselling to deliver HAP.
      Conclusion: This psychosocial support package is acceptable to patients. The information materials we developed are feasible to deliver in the current NTP. However, the structured psychological counselling (HAP), is not feasible in the current NTP due to time constraints. This requires additional investment of counsellors in TB clinics.
      Competing Interests: The authors have declared that no competing interests exist.
    • References:
      JAMA. 1999 Nov 10;282(18):1737-44. (PMID: 10568646)
      Soc Psychiatry Psychiatr Epidemiol. 2005 Aug;40(8):672-9. (PMID: 16021344)
      BMC Public Health. 2014 Jan 17;14:46. (PMID: 24438351)
      Glob Public Health. 2007;2(4):404-17. (PMID: 19283636)
      PLoS One. 2016 Jan 25;11(1):e0147397. (PMID: 26807933)
      BMC Med Res Methodol. 2013 Sep 18;13:117. (PMID: 24047204)
      Gen Hosp Psychiatry. 2013 Jul-Aug;35(4):398-406. (PMID: 23660587)
      Lancet. 2007 Sep 8;370(9590):859-77. (PMID: 17804063)
      Br J Psychiatry. 2016 Apr;208(4):381-8. (PMID: 26494875)
      BMC Psychiatry. 2016 Mar 08;16:58. (PMID: 26951403)
      Behav Sci. 1974 Jan;19(1):1-15. (PMID: 4808738)
      Br J Psychiatry. 2016 Jan;208 Suppl 56:s21-8. (PMID: 26447173)
      Int J Tuberc Lung Dis. 2017 Jun 1;21(6):603-609. (PMID: 28482954)
      PLoS One. 2017 Jan 18;12(1):e0167559. (PMID: 28099475)
      J Pers Assess. 1990 Winter;55(3-4):610-7. (PMID: 2280326)
      Lancet. 2017 Jan 14;389(10065):176-185. (PMID: 27988143)
      Lancet. 2016 Aug 27;388(10047):871-80. (PMID: 27461440)
      Tuberc Res Treat. 2013;2013:489865. (PMID: 23691305)
    • Publication Date:
      Date Created: 20180727 Date Completed: 20190117 Latest Revision: 20220408
    • Publication Date:
      20240104
    • Accession Number:
      PMC6062069
    • Accession Number:
      10.1371/journal.pone.0201163
    • Accession Number:
      30048495